Please login to the form below

Not currently logged in
Email:
Password:

BMS sells APAC assets

Taisho of Japan has agreed to buy BMS' OTC portfolio in Asia Pacific and its stake in BMSI

US pharma company, Bristol-Myers Squibb (BMS) has agreed to sell its over-the-counter (OTC) assets in Asia Pacific (APAC), excluding China and Japan, to Japanese firm Taisho Pharmaceutical for $310m.

Under the deal, Taisho will acquire certain product registrations, trademarks and related assets of selected pharmaceutical and OTC products sold primarily in Indonesia, Thailand and the Philippines, as well as other Asia Pacific countries. The products include, Tempra, Counterpain, Theragran-M, Engran, Ceetrus and Keri.

The deal also includes BMS' 97.97 per cent stake in PT BMS Indonesia (BMSI) and the land, buildings, product registrations, intellectual property, fixed assets, inventory and other related assets owned by BMSI. Both companies expect the deal to complete in quarter four 2009.

All 126 permanent BMSI employees will transfer to Taisho – subject to their rights under law.

"This planned divesture is a part of BMS' strategic transformation into a more focused next-generation biopharma company that develops and commercialises products that address serious unmet medical needs," said Dieter Weinard, president, intercontinental, BMS.

"The company is looking closely at its geographic and manufacturing footprint to align more closely to the scale and size of a biopharma company," he added.

HSBC acted as exclusive financial adviser to BMS on the deal.

16th September 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
ABPI2018
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....

Infographics